ID

41108

Descrição

A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS); ODM derived from: https://clinicaltrials.gov/show/NCT02188706

Link

https://clinicaltrials.gov/show/NCT02188706

Palavras-chave

Versões (1)
  1. 25/06/2020 25/06/2020 -
Titular dos direitos

See clinicaltrials.gov

Transferido a

25 de junho de 2020

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Leukemia NCT02188706

Inglês

Eligibility Leukemia NCT02188706

1 Formulários  
  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT02188706
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. patients with aml, relapsed or refractory to standard therapy or elderly patients with aml (age 65 or over). patients who have aml and are younger than age 65 but considered unfit for conventional chemotherapy are eligible. patients with de novo or treated mds or cmml int-1 or above are eligible. patients may have had prior exposure to azacitidine but no more than one cycle of decitabine. patients must have been off chemotherapy for 2 weeks prior to entering this study and have recovered from the toxicities of that therapy; a caveat to this is in the case of rapidly progressive disease. hydroxyurea is permitted for control of elevated wbc prior to treatment and can be continued for the first 4 weeks of therapy. erythropoiesis stimulating agents (esas) and gcsf are allowed before therapy. esas, gcsf or other growth factors are permitted on therapy.
Descrição

Recurrent Acute Myeloid Leukemia | AML Unresponsive to Standard therapy | AML Elderly | Age | Patient unfit for Chemotherapy | MYELODYSPLASTIC SYNDROME de novo IPSS | MYELODYSPLASTIC SYNDROME Treated IPSS | CMML IPSS | Exposure to azacitidine | decitabine | Toxicity Due to Therapy | Patient recovered | hydroxyurea | Erythropoiesis-stimulating Agent | Granulocyte Colony-Stimulating Factor | Growth Factor

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1142169
UMLS CUI [2,1]
C0023467
UMLS CUI [2,2]
C0205269
UMLS CUI [2,3]
C2936643
UMLS CUI [3,1]
C0023467
UMLS CUI [3,2]
C0001792
UMLS CUI [4]
C0001779
UMLS CUI [5,1]
C3839996
UMLS CUI [5,2]
C0392920
UMLS CUI [6,1]
C3463824
UMLS CUI [6,2]
C1515568
UMLS CUI [6,3]
C2827405
UMLS CUI [7,1]
C3463824
UMLS CUI [7,2]
C1522326
UMLS CUI [7,3]
C2827405
UMLS CUI [8,1]
C0023480
UMLS CUI [8,2]
C2827405
UMLS CUI [9,1]
C0332157
UMLS CUI [9,2]
C0004475
UMLS CUI [10]
C0049065
UMLS CUI [11,1]
C0600688
UMLS CUI [11,2]
C0678226
UMLS CUI [11,3]
C0087111
UMLS CUI [12]
C1115804
UMLS CUI [13]
C0020402
UMLS CUI [14]
C2917382
UMLS CUI [15]
C0079459
UMLS CUI [16]
C0018284
2. performance 0-2 (ecog).
Descrição

ECOG performance status

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1520224
3. adequate cardiac functions assessed by 2d echo (nyha cardiac iii-iv excluded).
Descrição

Cardiac function Echocardiography second | New York Heart Association Classification

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0232164
UMLS CUI [1,2]
C0013516
UMLS CUI [1,3]
C0205436
UMLS CUI [2]
C1275491
4. pre-treatment ekg
Descrição

ECG pre treatment

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0013798
UMLS CUI [1,2]
C2709094
5. adequate end organ function with creatinine </= 2mg/dl and total bilirubin </= 2mg/dl, ast and alt </= or = 2.5 x institutional uln.
Descrição

Organ function | Creatinine measurement, serum | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0678852
UMLS CUI [2]
C0201976
UMLS CUI [3]
C1278039
UMLS CUI [4]
C0201899
UMLS CUI [5]
C0201836
6. absence of significant intercurrent illness such as uncontrolled heart failure, unstable angina, cardiac arrhythmia and psychiatric illness which precludes the giving of informed consent.
Descrição

Comorbidity Significant;Absent | Absence Heart failure Uncontrolled | Unstable Angina Absent | Cardiac Arrhythmia Absent | Mental disorders Absent | Mental disorders Exclude Informed Consent

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0750502
UMLS CUI [1,3]
C0332197
UMLS CUI [2,1]
C0332197
UMLS CUI [2,2]
C0018801
UMLS CUI [2,3]
C0205318
UMLS CUI [3,1]
C0002965
UMLS CUI [3,2]
C0332197
UMLS CUI [4,1]
C0003811
UMLS CUI [4,2]
C0332197
UMLS CUI [5,1]
C0004936
UMLS CUI [5,2]
C0332197
UMLS CUI [6,1]
C0004936
UMLS CUI [6,2]
C0332196
UMLS CUI [6,3]
C0021430
7. signed informed consent
Descrição

Informed Consent

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. nursing and pregnant females. patients of childbearing potential should practice effective methods of contraception. should a woman become preg-nant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
Descrição

Breast Feeding | Pregnancy | Childbearing Potential Contraceptive methods

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0006147
UMLS CUI [2]
C0032961
UMLS CUI [3,1]
C3831118
UMLS CUI [3,2]
C0700589
2. current uncontrolled infections.
Descrição

Communicable Disease Uncontrolled

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0205318
3. uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements.
Descrição

Comorbidity Uncontrolled | Symptomatic congestive heart failure | Angina, Unstable | Mental disorders Limiting Protocol Compliance | Social situation Limiting Protocol Compliance

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205318
UMLS CUI [2]
C0742758
UMLS CUI [3]
C0002965
UMLS CUI [4,1]
C0004936
UMLS CUI [4,2]
C0439801
UMLS CUI [4,3]
C0525058
UMLS CUI [5,1]
C0748872
UMLS CUI [5,2]
C0439801
UMLS CUI [5,3]
C0525058
4. chronic kidney disease > stage 3.
Descrição

Chronic Kidney Disease Stage

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1561643
UMLS CUI [1,2]
C2074731
5. hiv infection.
Descrição

HIV Infection

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0019693
Voltar ao início da página

Similar models

Eligibility Leukemia NCT02188706

1 Formulários
  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT02188706
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Recurrent Acute Myeloid Leukemia | AML Unresponsive to Standard therapy | AML Elderly | Age | Patient unfit for Chemotherapy | MYELODYSPLASTIC SYNDROME de novo IPSS | MYELODYSPLASTIC SYNDROME Treated IPSS | CMML IPSS | Exposure to azacitidine | decitabine | Toxicity Due to Therapy | Patient recovered | hydroxyurea | Erythropoiesis-stimulating Agent | Granulocyte Colony-Stimulating Factor | Growth Factor
Item
1. patients with aml, relapsed or refractory to standard therapy or elderly patients with aml (age 65 or over). patients who have aml and are younger than age 65 but considered unfit for conventional chemotherapy are eligible. patients with de novo or treated mds or cmml int-1 or above are eligible. patients may have had prior exposure to azacitidine but no more than one cycle of decitabine. patients must have been off chemotherapy for 2 weeks prior to entering this study and have recovered from the toxicities of that therapy; a caveat to this is in the case of rapidly progressive disease. hydroxyurea is permitted for control of elevated wbc prior to treatment and can be continued for the first 4 weeks of therapy. erythropoiesis stimulating agents (esas) and gcsf are allowed before therapy. esas, gcsf or other growth factors are permitted on therapy.
boolean
C1142169 (UMLS CUI [1])
C0023467 (UMLS CUI [2,1])
C0205269 (UMLS CUI [2,2])
C2936643 (UMLS CUI [2,3])
C0023467 (UMLS CUI [3,1])
C0001792 (UMLS CUI [3,2])
C0001779 (UMLS CUI [4])
C3839996 (UMLS CUI [5,1])
C0392920 (UMLS CUI [5,2])
C3463824 (UMLS CUI [6,1])
C1515568 (UMLS CUI [6,2])
C2827405 (UMLS CUI [6,3])
C3463824 (UMLS CUI [7,1])
C1522326 (UMLS CUI [7,2])
C2827405 (UMLS CUI [7,3])
C0023480 (UMLS CUI [8,1])
C2827405 (UMLS CUI [8,2])
C0332157 (UMLS CUI [9,1])
C0004475 (UMLS CUI [9,2])
C0049065 (UMLS CUI [10])
C0600688 (UMLS CUI [11,1])
C0678226 (UMLS CUI [11,2])
C0087111 (UMLS CUI [11,3])
C1115804 (UMLS CUI [12])
C0020402 (UMLS CUI [13])
C2917382 (UMLS CUI [14])
C0079459 (UMLS CUI [15])
C0018284 (UMLS CUI [16])
ECOG performance status
Item
2. performance 0-2 (ecog).
boolean
C1520224 (UMLS CUI [1])
Cardiac function Echocardiography second | New York Heart Association Classification
Item
3. adequate cardiac functions assessed by 2d echo (nyha cardiac iii-iv excluded).
boolean
C0232164 (UMLS CUI [1,1])
C0013516 (UMLS CUI [1,2])
C0205436 (UMLS CUI [1,3])
C1275491 (UMLS CUI [2])
ECG pre treatment
Item
4. pre-treatment ekg
boolean
C0013798 (UMLS CUI [1,1])
C2709094 (UMLS CUI [1,2])
Organ function | Creatinine measurement, serum | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
5. adequate end organ function with creatinine </= 2mg/dl and total bilirubin </= 2mg/dl, ast and alt </= or = 2.5 x institutional uln.
boolean
C0678852 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
C1278039 (UMLS CUI [3])
C0201899 (UMLS CUI [4])
C0201836 (UMLS CUI [5])
Comorbidity Significant;Absent | Absence Heart failure Uncontrolled | Unstable Angina Absent | Cardiac Arrhythmia Absent | Mental disorders Absent | Mental disorders Exclude Informed Consent
Item
6. absence of significant intercurrent illness such as uncontrolled heart failure, unstable angina, cardiac arrhythmia and psychiatric illness which precludes the giving of informed consent.
boolean
C0009488 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0332197 (UMLS CUI [2,1])
C0018801 (UMLS CUI [2,2])
C0205318 (UMLS CUI [2,3])
C0002965 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0003811 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
C0004936 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
C0004936 (UMLS CUI [6,1])
C0332196 (UMLS CUI [6,2])
C0021430 (UMLS CUI [6,3])
Informed Consent
Item
7. signed informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Breast Feeding | Pregnancy | Childbearing Potential Contraceptive methods
Item
1. nursing and pregnant females. patients of childbearing potential should practice effective methods of contraception. should a woman become preg-nant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
boolean
C0006147 (UMLS CUI [1])
C0032961 (UMLS CUI [2])
C3831118 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
Communicable Disease Uncontrolled
Item
2. current uncontrolled infections.
boolean
C0009450 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
Comorbidity Uncontrolled | Symptomatic congestive heart failure | Angina, Unstable | Mental disorders Limiting Protocol Compliance | Social situation Limiting Protocol Compliance
Item
3. uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements.
boolean
C0009488 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0742758 (UMLS CUI [2])
C0002965 (UMLS CUI [3])
C0004936 (UMLS CUI [4,1])
C0439801 (UMLS CUI [4,2])
C0525058 (UMLS CUI [4,3])
C0748872 (UMLS CUI [5,1])
C0439801 (UMLS CUI [5,2])
C0525058 (UMLS CUI [5,3])
Chronic Kidney Disease Stage
Item
4. chronic kidney disease > stage 3.
boolean
C1561643 (UMLS CUI [1,1])
C2074731 (UMLS CUI [1,2])
HIV Infection
Item
5. hiv infection.
boolean
C0019693 (UMLS CUI [1])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial